I did the pharmacokinetic analysis because I had a hunch that DMT's PK profile was probably similar to many general anaesthetics - I brought Strassman into the fold since he had the original blood data from his 90s study. The point of the article was really as a proof-of-principle that the target-controlled continuous IV technology would work with DMT. and to explore some of the potential applications of such a technology. Of course, ideally, in the future someone (me? Strassman? not sure yet) could implement the model in a human study (actually, the Imperial team were going to do so for their new (and ongoing) DMT study, but opted for bolus at the last minute since it was felt infusion was a step too far for a first study). It's a first step basically